Cholera Phage Program

About PhagePro

PhagePro is a private, pre-clinical stage biotech leveraging naturally occurring bacteriophages to create targeted antibacterial therapies, with an initial focus on cholera. The company differentiates itself through a strong commitment to global health equity, seeking to deploy its solutions in low-resource settings hardest hit by antibiotic resistance. While still early-stage and pre-revenue, it operates at the intersection of innovative science, public policy, and community-focused commercialization to tackle urgent public health threats.

Therapeutic Areas